Correlation between hormonal and lipid status in women in menopause

Bosnian Journal of Basic Medical Sciences

Volumn 8, Issue 2, 2008, Pages 188-192

  Mešalić, Lejla ^a   Tupković, Emir ^a   Kendić, Sulejman ^b   Balić, Devleta ^c  

^a Health Center Tuzla   (Bosnia and Herzegovina)

^b Private Clinic MedicoOral AS Biha   (Bosnia and Herzegovina)

^c UNIVERSITY CLINICAL CENTER TUZLA   (Bosnia and Herzegovina)

Author keywords

FSH; HDL; LDL; LH; Lipid status; Menopause; Triglycerides

Indexed keywords

CHOLESTEROL; ESTRADIOL; FOLLITROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE;

ADULT; AGED; ARTICLE; BLOOD; CHEMISTRY; FEMALE; HUMAN; MENOPAUSE; METABOLISM; MIDDLE AGED;

ADULT; AGED; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HORMONES; HUMANS; LIPIDS; LIPOPROTEINS; LUTEINIZING HORMONE; MENOPAUSE; MIDDLE AGED;

EID: 55949093545     PISSN: 15128601     EISSN: None     Source Type: Journal    
DOI: 10.17305/bjbms.2008.2980     Document Type: Article

References (21)

1. Carr M.C., Kim KH, Zambon A., Mitchell E.S., Woods N.F., Casa-zza C.P., Purnell J.Q., Hokanson J.E., Brunzell J.D., Schwarz R.S.. Changes in LDL density across the menopausal transition. J. Invest. Med. 2000; 48:245-250.
2. Lamarche B., Moorjani S., Cantin B., Dagenais G.R., Lupien P.J., Despers J.P. Association of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Quebec cardiovascular study. Arterioscler. Thromb. Vasc. Biol. 1997; 17:1098-1105.
3. Gower B.A., Naggy T.R., Goran M.I., Toth M.J., Poehlman E.T. Fat distribution and plasma lipid-lipoprotein concentrations in pre- and postmenopausal women. Int. J. Obes. Relat. Metab. Dis-ord. 1998; 22 (7): 605-611.
4. Van Beek A.P., de Rujiter-Heistek F.C., Jansen H., Erkelens D.W. Sex steroids and plasma lipoprotein levels in healthy women: importance of androgens in the estrogen-deficient state. Metabolism 2004:53 (2): 187-192.
5. Onat A., Yazici M., Can G., Sniderman A. Evidence for a complex risk profile in obese postmenopausal Turkish women with hyper-triglyceridemia and elevated apoliptoprotein B. Clin. Sci. (Lond) 2004; 107(1): 97-104.
6. Ikenoue N., Wakatsuki A., Okatani Y. Small low- density lipoprotein particles in women with natural or surgically induced menopause. Obst. Gynecol. 1999; 93(4): 566-570.
7. Goholke-Barwolf C. Coronary artery disease-is menopause a risk factor? Basic Res Cardiol 2000; 1:177-183.
8. Guthrie J.R., Taffe J.R., Lehert P., Burger H.G., Dennerstein L. Association between hormonal changes at menopause and the risk of a coronary event: a longitudinal study. Menopause 2004; 11 (3): 315-322.
9. Berg G., Mesh V., Boero L., Sayegh F., Prada M., Royer M., Muzz-io M.L., Schreier L., Sisele N., Benanacia H. Lipid and lipoprotein profile in menopausal transition. Effects of hormones, age and fat distribution. Horm. Metab. Res. 2004; 36(4): 215-220.
10. Sultan N., Nawaz M., Sultan A., Fayaz M., Baseer A. Effect of menopause on serum HDL-cholesterol level. J. Ayub. Med. Coll. Abbottabad. 2003; 15(3): 24-26
11. Limouzin-Lamothe M.A. Cardiovascular impact of therapy and risks In: Frome, Somerset, Butler and Tanner. The Climacteric an update 1984; 217-239.
12. Shecter M., Bairey M., Maura J.P, Prediman K.S., Sanjay K. Plasma Apolipoprotein B levels Predict Platelet-Dependent Thrombosis in Patients with Coronary Artery Disease. Cardiology 1999; 92:151-155.
13. Walldius G., Junger I. Apolipoprotein B and apolipoprotein A-i: risk indicators of coronary heart disease and targets for lipid modifyng therapy. J. Int. Med. 2004; 255:188-193.
14. Manfroi W.C., Zago A.J., Campos M., Alves A., Brisolara M.L., de Soza J., Candiago R.H., Kirschnick L., Ribeiro L., Ordovas K., Keitao C., Cruz R. Are apolipoproteins A and B better than lipo-proteins for assessing of obstructive coronary heart disease. Arq. Bras. Cardiol. 1999; 72(6): 657-658.
15. Clarkson T.B., Appt S.E. MPA and postmenopausal coronary artery atherosclerosis revisited. Steroids 2003; 68:941-951.
16. Dahlen G.H. (Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis 1994; 108:111-126.
17. Esplendad M.A.,Bush T.L.,Mebane-Sims I.,Stefanik M.L., Johnson S., Sherwin R., Waclawiw M. Rationale design and conduct of the PEPI trial. Control.Clin.Trials 1995:16:3-19.
18. Davison S., Davis S. New markers for Cardiovascular Disease Risk in Women: Impact of Endogenous Estrogen Status and Exogenous Postmenopausal Hormone Therapy. J. Clin Endocrinol. Metabol. 2003; 88:2470-2478.
19. Gong M., Wilson M., Kelly T., Su W., Dressman J., Kincer J., Matveev S.V., Guo L., Guerin T., Li X., Zhu W., Uittenbogaard A., Smart E. HDL-associated estradiol stimulates endothelial NO Synthase vasodilatation in an SR-BI dependent manner.J.Clin. Invest. 2003:111:1579-1587.
20. Koba S., Hirano T., Sakaue T., Takeuchi H., Adachi M., Katagiri T. An increased number of very-low-density lipoprotein particles are strongly associated with coronary heart disease in Japanese independently of intermediate-density lipoprotein or low-density lipoprotein. Coron. Artery Dis. 2002; 13(5): 255-262.
21. Chu M., Rath K.M., Huie J., Taylor H.S. Elevated basal FSH i normal cycling women is associated with unfavorable lipid levels and increased cardiovascular risk. Hum. Reprod. 2003; 18(8): 1570-1573.